Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy.
Morten WürtzKevin Kris Warnakula OlesenDeepak L BhattSalim YusufEva MuehlhoferJohn W EikelboomMichael MaengPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
As classified by the CHADS-P2A2RC score, low/moderate- and high-risk patients with CCS derived similar net clinical benefit and reduction in all-cause death from DPI treatment.